Cue Biopharma, Inc. (CUE)
23.18
-0.80
(-3.34%)
USD |
NASDAQ |
Aug 24, 16:00
23.16
-0.02
(-0.09%)
After-Hours: 20:00
Cue Biopharma EPS Diluted (Quarterly) : -24.14 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -24.14 |
| March 31, 2026 | -1.077 |
| December 31, 2025 | 0.4302 |
| September 30, 2025 | -2.215 |
| June 30, 2025 | -2.666 |
| March 31, 2025 | -0.1651 |
| December 31, 2024 | -3.837 |
| September 30, 2024 | -0.169 |
| June 30, 2024 | -0.2027 |
| March 31, 2024 | -0.2496 |
| December 31, 2023 | -0.285 |
| September 30, 2023 | -0.2374 |
| June 30, 2023 | -0.2943 |
| March 31, 2023 | -0.2936 |
| December 31, 2022 | -0.3725 |
| September 30, 2022 | -0.3096 |
| June 30, 2022 | -0.3736 |
| March 31, 2022 | -0.4368 |
| December 31, 2021 | -0.2604 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.4123 |
| June 30, 2021 | -0.3291 |
| March 31, 2021 | -0.4109 |
| December 31, 2020 | -0.3658 |
| September 30, 2020 | -0.3383 |
| June 30, 2020 | -0.3839 |
| March 31, 2020 | -0.4824 |
| December 31, 2019 | -0.3627 |
| September 30, 2019 | -0.3114 |
| June 30, 2019 | -0.4573 |
| March 31, 2019 | -0.5438 |
| December 31, 2018 | -0.5757 |
| September 30, 2018 | -0.6238 |
| June 30, 2018 | -0.3626 |
| March 31, 2018 | -0.375 |
| December 31, 2017 | -0.5364 |
| September 30, 2017 | -14.19 |
| September 30, 2016 | -0.1048 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 0.3068 |
| Fortress Biotech, Inc. | -0.0779 |
| Equillium, Inc. | -0.042 |
| Legend Biotech Corp. | 0.1716 |
| Nurix Therapeutics, Inc. | -0.806 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -153.07M |
| Revenue (Quarterly) | 7.877M |
| Total Expenses (Quarterly) | 160.94M |
| Enterprise Value | 112.63M |
| Gross Profit Margin (Quarterly) | 99.54% |
| Profit Margin (Quarterly) | -1.94K% |
| Earnings Yield | -116.5% |
| Normalized Earnings Yield | -128.16 |